Tags

Type your tag names separated by a space and hit enter

Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant.
Biochem Biophys Res Commun 1992; 182(1):247-53BB

Abstract

Twenty years of international open and seven double blind trials established the efficacy and safety of coenzyme Q10 (CoQ10) to treat patients in heart failure. In the U.S., ca. 20,000 patients under 65 years are eligible for transplants, but donors are less than 1/10th of those eligible, and there are many more such patients over 65, both eligible and ineligible. We treated eleven exemplary transplant candidates with CoQ10; all improved; three improved from Class IV to Class I; four improved from Classes III-IV to Class II; and two improved from Class III to Class I or II. After CoQ10, some patients required no conventional drugs and had no limitation in lifestyle. The marked improvement is based upon correcting myocardial deficiencies of CoQ10 which improve mitochondrial bioenergetics and cardiac performance. These case histories, and very substantial background proof of efficacy and safety, justify treating with CoQ10 patients in failure awaiting transplantation.

Authors+Show Affiliations

Institute for Biomedical Research, University of Texas, Austin 78712.No affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1731784

Citation

Folkers, K, et al. "Therapy With Coenzyme Q10 of Patients in Heart Failure Who Are Eligible or Ineligible for a Transplant." Biochemical and Biophysical Research Communications, vol. 182, no. 1, 1992, pp. 247-53.
Folkers K, Langsjoen P, Langsjoen PH. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys Res Commun. 1992;182(1):247-53.
Folkers, K., Langsjoen, P., & Langsjoen, P. H. (1992). Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochemical and Biophysical Research Communications, 182(1), pp. 247-53.
Folkers K, Langsjoen P, Langsjoen PH. Therapy With Coenzyme Q10 of Patients in Heart Failure Who Are Eligible or Ineligible for a Transplant. Biochem Biophys Res Commun. 1992 Jan 15;182(1):247-53. PubMed PMID: 1731784.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. AU - Folkers,K, AU - Langsjoen,P, AU - Langsjoen,P H, PY - 1992/1/15/pubmed PY - 1992/1/15/medline PY - 1992/1/15/entrez SP - 247 EP - 53 JF - Biochemical and biophysical research communications JO - Biochem. Biophys. Res. Commun. VL - 182 IS - 1 N2 - Twenty years of international open and seven double blind trials established the efficacy and safety of coenzyme Q10 (CoQ10) to treat patients in heart failure. In the U.S., ca. 20,000 patients under 65 years are eligible for transplants, but donors are less than 1/10th of those eligible, and there are many more such patients over 65, both eligible and ineligible. We treated eleven exemplary transplant candidates with CoQ10; all improved; three improved from Class IV to Class I; four improved from Classes III-IV to Class II; and two improved from Class III to Class I or II. After CoQ10, some patients required no conventional drugs and had no limitation in lifestyle. The marked improvement is based upon correcting myocardial deficiencies of CoQ10 which improve mitochondrial bioenergetics and cardiac performance. These case histories, and very substantial background proof of efficacy and safety, justify treating with CoQ10 patients in failure awaiting transplantation. SN - 0006-291X UR - https://www.unboundmedicine.com/medline/citation/1731784/Therapy_with_coenzyme_Q10_of_patients_in_heart_failure_who_are_eligible_or_ineligible_for_a_transplant_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(05)80137-8 DB - PRIME DP - Unbound Medicine ER -